Patents by Inventor Donglai Yang

Donglai Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method and apparatus for controlling motorcycle, system, motorcycle and storage medium
    Patent number: 12173665
    Abstract: The present application discloses a method and apparatus for controlling a motorcycle, a system, a motorcycle and a storage medium. The method includes: acquiring a first wheel speed signal and a second wheel speed signal; calculating a difference between the first wheel speed signal and the second wheel speed signal; detecting whether the difference satisfies a first condition, the first condition being used for detecting whether to adjust ignition timing of an engine; if the difference satisfies the first condition, detecting whether the exhaust temperature of the engine exceeds a temperature threshold; if the exhaust temperature does not exceed the temperature threshold, determining an ignition plug ignition angle of the engine according to the difference and the rotating speed of the engine; and adjusting the ignition timing of the engine according to the ignition plug ignition angle.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 24, 2024
    Assignee: United Automotive Electronic Systems Co., Ltd.
    Inventors: Shilei Guo, Qiang Li, Xuemin Jiang, Xinghong Jiang, Qiang Yu, Yincheng Zhou, Donglai Yang
  • PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS
    Publication number: 20240189223
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Application
    Filed: October 20, 2023
    Publication date: June 13, 2024
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • METHOD AND APPARATUS FOR CONTROLLING MOTORCYCLE, SYSTEM, MOTORCYCLE AND STORAGE MEDIUM
    Publication number: 20230383706
    Abstract: The present application discloses a method and apparatus for controlling a motorcycle, a system, a motorcycle and a storage medium. The method includes: acquiring a first wheel speed signal and a second wheel speed signal; calculating a difference between the first wheel speed signal and the second wheel speed signal; detecting whether the difference satisfies a first condition, the first condition being used for detecting whether to adjust ignition timing of an engine; if the difference satisfies the first condition, detecting whether the exhaust temperature of the engine exceeds a temperature threshold; if the exhaust temperature does not exceed the temperature threshold, determining an ignition plug ignition angle of the engine according to the difference and the rotating speed of the engine; and adjusting the ignition timing of the engine according to the ignition plug ignition angle.
    Type: Application
    Filed: September 27, 2021
    Publication date: November 30, 2023
    Applicant: United Automotive Electronic Systems Co., Ltd.
    Inventors: Shilei GUO, Qiang LI, Xuemin JIANG, Xinghong JIANG, Qiang YU, Yincheng ZHOU, Donglai YANG
  • Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
    Patent number: 11793749
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: October 24, 2023
    Assignee: Genzyme Corporation
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS
    Publication number: 20220110861
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Application
    Filed: August 20, 2021
    Publication date: April 14, 2022
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
    Patent number: 11110055
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 7, 2021
    Assignee: Genzyme Corporation
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS
    Publication number: 20200048222
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Application
    Filed: January 4, 2019
    Publication date: February 13, 2020
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos
  • Pharmaceutical formulations of tropomyosin related kinase (Trk) inhibitors
    Patent number: 10219998
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 5, 2019
    Assignee: Genzyme Corporation
    Inventors: Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
  • PHARMACEUTICAL FORMULATIONS OF TROPOMYOSIN RELATED KINASE (TRK) INHIBITORS
    Publication number: 20180000728
    Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
    Type: Application
    Filed: December 17, 2015
    Publication date: January 4, 2018
    Applicant: GENZYME CORPORATION
    Inventors: Harvey LIEBERMAN, Donglai YANG, C. Michael PHILBROOK, Michael SANTOS, Chris HO
  • Forms of rifaximin and uses thereof
    Patent number: 9700545
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: July 11, 2017
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Forms of rifaximin and uses thereof
    Patent number: 9546183
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 17, 2017
    Assignee: Salix Pharmaceuticals, Ltd
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20160317507
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 3, 2016
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20160200738
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 14, 2016
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Forms of rifaximin and uses thereof
    Patent number: 9359357
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 7, 2016
    Assignees: Salix Pharmaceuticals, Ltd., Alfa Wassermann S.P.A.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Forms of rifaximin and uses thereof
    Patent number: 9273066
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: March 1, 2016
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Forms of rifaximin and uses thereof
    Patent number: 9181274
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: November 10, 2015
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20150299199
    Abstract: The present invention relates to Rifaximin amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: December 23, 2014
    Publication date: October 22, 2015
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Giuseppe Claudio Viscomi
  • Forms of rifaximin and uses thereof
    Patent number: 9034892
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: May 19, 2015
    Assignee: Salix Pharmaceuticals, Inc.
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • FORMS OF RIFAXIMIN AND USES THEREOF
    Publication number: 20140179916
    Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Application
    Filed: October 24, 2013
    Publication date: June 26, 2014
    Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
  • Forms of rifaximin and uses thereof
    Patent number: 8754098
    Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: June 17, 2014
    Assignee: Salix Pharmaceuticals, Ltd.
    Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston